Theravance Biopharma Inc (NASDAQ:TBPH) Short Interest Update

Theravance Biopharma Inc (NASDAQ:TBPH) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 5,202,500 shares, a decline of 7.5% from the June 30th total of 5,626,300 shares. Based on an average daily volume of 303,500 shares, the short-interest ratio is currently 17.1 days. Currently, 12.4% of the company’s stock are sold short.

A number of brokerages have commented on TBPH. Piper Jaffray Companies set a $55.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, July 31st. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Theravance Biopharma has an average rating of “Buy” and a consensus target price of $44.25.

TBPH traded down $0.02 during midday trading on Thursday, reaching $21.27. 217,962 shares of the company were exchanged, compared to its average volume of 252,225. The company’s fifty day moving average price is $18.58 and its 200 day moving average price is $21.23. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -5.33 and a beta of 1.75. Theravance Biopharma has a one year low of $15.18 and a one year high of $35.48.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.50. The company had revenue of $26.15 million during the quarter, compared to analyst estimates of $13.92 million. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. On average, sell-side analysts forecast that Theravance Biopharma will post -4.28 EPS for the current year.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $20.46, for a total transaction of $81,840.00. Following the completion of the sale, the director now directly owns 30,244 shares of the company’s stock, valued at approximately $618,792.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.60% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Theravance Biopharma in the first quarter valued at approximately $156,000. CWM Advisors LLC purchased a new position in Theravance Biopharma in the second quarter valued at approximately $167,000. BNP Paribas Arbitrage SA lifted its stake in Theravance Biopharma by 882.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 8,951 shares during the last quarter. Nisa Investment Advisors LLC purchased a new position in Theravance Biopharma in the first quarter valued at approximately $254,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in Theravance Biopharma by 64.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 7,500 shares during the last quarter. 83.83% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: What is a Futures Contract?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.